title: Immunophenotypization of cells involved in local immune response and serum antibodies in cephalosporin-treated mice.
abstract: The in vivo potency of cefodizime (HR 221), tiprotimod (a new synthetic thiazole derivative of HR 221, HBW 538) and cefotaxime to modulate the initiation of immune response in the draining lymph node (LN) after subcutaneous injection of SRBC was evaluated. The timing and sequence of events in the regional LN was investigated by immunophenotypization of node cells with monoclonal antibodies, and the systemic reaction was estimated as primary antibody response to SRBC. From the results it is possible to conclude that: (1) subcutaneous administration of a small dose (2.5-3.0 mg/kg) of cephalosporins, together with antigen, enhanced primary antibody production and persistence; (2) the increase in serum antibodies was preceded by a change in percentage of L3T4+ cells within the regional (popliteal) lymph node. In comparison to antigen alone, cephalosporins (during early immune response) increased the percentage of L3T4+ cells; (3) LN cellularity was strongly enhanced by cephalosporins; (4) cefotaxime influenced the kinetics of the cellularity and the L3T4/Lyt-2 index differently than cefodizime and HBW 538. HBW 538 had either a similar or stronger effect than cefodizime, as judged by the adjuvant effect on antibody production and the appearance of L3T4+ cells during the immunizing period.
authors.affiliation: Institute of Immunology, Zagreb, Yugoslavia.
authors.forename: R
authors.initials: R
authors.lastname: Mazuran
authors.forename: J
authors.initials: J
authors.lastname: Tomasić
authors.forename: G
authors.initials: G
authors.lastname: Broketa
authors.forename: E
authors.initials: E
authors.lastname: Schrinner
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D000917:Antibody Formation / Q000187:drug effects* / Q000276:immunology; D000941:Antigens / Q000276:immunology; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006984:Hypertrophy / Q000276:immunology; D016130:Immunophenotyping; D007518:Isoantibodies / Q000276:immunology; D008198:Lymph Nodes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D051379:Mice; D008808:Mice, Inbred CBA; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D000941:Antigens; D002511:Cephalosporins; D007518:Isoantibodies; C029805:Lyt antibodies; D002439:Cefotaxime; C033356:cefodizime